Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
Vet Microbiol ; 239: 108488, 2019 Dec.
Article in English | MEDLINE | ID: mdl-31767066

ABSTRACT

Acriflavine, an acridine dye that causes frameshift mutations, has been used to attenuate various veterinary pathogens for the development of live vaccines. Erysipelothrix rhusiopathiae Koganei 65-0.15 strain (Koganei) (serovar 1a) is the acriflavine-resistant live vaccine currently used in Japan for the control of swine erysipelas. To investigate the attenuation mechanisms of the Koganei strain, we analyzed the draft genome sequence of the Koganei strain against the reference genome sequence of the E. rhusiopathiae Fujisawa strain (serovar 1a). The sequence analysis revealed a high degree of sequence similarity between the two strains and identified a total of 98 sequence differences within 80 protein-coding sequences. Among them, insertions/deletions (indels) were identified in 9 genes, of which 7 resulted in frameshift and premature termination. To investigate whether these mutations resulted in the attenuation of the Koganei strain, we focused on the indel mutation identified in ERH_0661, an XRE family transcriptional regulator. We introduced the mutation into ERH_0661 of the Fujisawa strain and restored the mutation of the Koganei strain. Animal experiments using the recombinant strains showed that mice survived inoculation with 103 colony forming units (CFUs) (equivalent to approximately 100 50% lethal doses [LD50] of the wild-type Fujisawa) of the recombinant Fujisawa strain, and the mice became ill after inoculation with 108 CFUs of the recombinant Koganei strain. These results suggest that the transcriptional regulator ERH_0661 is involved in the virulence of E. rhusiopathiae and that the ERH_0661 mutation is partially responsible for the attenuation of the Koganei strain.


Subject(s)
Erysipelothrix/genetics , Vaccines, Attenuated/genetics , Virulence/genetics , Acriflavine/pharmacology , Animals , Base Sequence , DNA, Bacterial/drug effects , DNA, Bacterial/genetics , Erysipelothrix/pathogenicity , Female , Genome, Bacterial/genetics , Mice , Mutation , Recombinant Proteins/genetics , Recombinant Proteins/immunology , Species Specificity , Virulence/drug effects
2.
Infect Immun ; 87(12)2019 12.
Article in English | MEDLINE | ID: mdl-31548316

ABSTRACT

Swine erysipelas is caused by the Gram-positive pathogen Erysipelothrix rhusiopathiae The swine erysipelas live vaccine in Japan, the E. rhusiopathiae Koganei 65-0.15 strain (Koganei), has been reported to cause arthritis and endocarditis. To develop a vaccine with increased safety, we used a virulent Fujisawa strain to construct transposon mutants for a total of 651 genes, which covered 38% of the coding sequence of the genome. We screened the mutants for attenuation by inoculating mice with 108 CFU of each mutant and subsequently assessed protective capability by challenging the surviving mice with 103 CFU (102 times the 50% lethal dose) of the Fujisawa strain. Of the 23 attenuated mutants obtained, 6 mutants were selected and evaluated for protective capability in pigs by comparison to that of the Koganei strain. A mutant in the ERH_0432 (tagF) gene encoding a putative CDP-glycerol glycerophosphotransferase was found to be highly attenuated and to induce humoral and cell-mediated immune responses in conventional pigs. An in-frame deletion mutant of the gene, the Δ432 mutant, was constructed, and attenuation was further confirmed in germfree piglets; three of four piglets subcutaneously inoculated with 109 CFU of the Δ432 mutant showed no apparent clinical symptoms, whereas all four of the Koganei-inoculated piglets died 3 days after inoculation. It was confirmed that conventional pigs inoculated orally or subcutaneously with the Δ432 strain were almost completely protected against lethal challenge infection. Thus, the tagF homolog mutant of E. rhusiopathiae represents a safe vaccine candidate that can be administered via the oral and subcutaneous routes.


Subject(s)
Bacterial Vaccines/immunology , Erysipelothrix Infections/prevention & control , Erysipelothrix/genetics , Erysipelothrix/immunology , Swine Diseases/prevention & control , Transferases (Other Substituted Phosphate Groups)/genetics , Animals , DNA Transposable Elements/genetics , Erysipelothrix/pathogenicity , Erysipelothrix Infections/immunology , Female , Mice , Swine , Swine Diseases/immunology , Swine Diseases/microbiology , Vaccines, Attenuated/immunology
3.
BMC Biotechnol ; 2: 16, 2002 Sep 12.
Article in English | MEDLINE | ID: mdl-12227831

ABSTRACT

BACKGROUND: Hep27 monoclonal (Hep27 Mab) is an antibody against hepatocellular carcinoma. Hep27 Mab itself can inhibit the growth of a hepatocellular carcinoma cell line (HCC-S102). We attempted to produce a single-chain fragment (scFv), a small fragment containing an antigen-binding site of Hep27 Mab, by using DNA-recombinant techniques. RESULTS: The sequences encoding the variable regions of heavy (VH) and light (VL) chains of a murine Hep27 Mab were linked together by a linker peptide (Gly4Ser)3 and tagged with a hexa-histidine at the C-terminal; the resultant DNA construct was expressed in E. coli as an insoluble protein. The denatured scFv was refolded and purified by immobilized metal ion affinity chromatography (12 mg/l with a molecular weight of 27 kDa). Hep27scFv exhibited a tumoricidal activity against the HCC-S102 cell as its parental antibody (Hep27 Mab). CONCLUSION: This scFv may be a potential candidate for a targeting agent in HCC immunodiagnosis or immunotherapy.


Subject(s)
Antibodies, Monoclonal/genetics , Antineoplastic Agents/metabolism , Carcinoma, Hepatocellular/drug therapy , Immunoglobulin Fragments/genetics , Liver Neoplasms/drug therapy , Amino Acid Sequence , Antibodies, Monoclonal/metabolism , Antibodies, Monoclonal/therapeutic use , Antineoplastic Agents/therapeutic use , Base Sequence , Carcinoma, Hepatocellular/immunology , Carcinoma, Hepatocellular/pathology , Cell Division/drug effects , Cytoplasm/metabolism , Gene Expression , Immunoglobulin Fragments/metabolism , Immunoglobulin Fragments/therapeutic use , Immunoglobulin Variable Region/genetics , Liver Neoplasms/immunology , Liver Neoplasms/pathology , Molecular Sequence Data , Protein Engineering , Protein Folding , Single-Chain Antibodies , Tumor Cells, Cultured
SELECTION OF CITATIONS
SEARCH DETAIL
...